Search Result

Results for "

oncologic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) EGFR (1) HIV Protease (1) JNK (1) MDM-2/p53 (1) Mixed Lineage Kinase (1) Monoamine Oxidase (1) Necroptosis (1) NF-κB (2) p38 MAPK (1) PARP (1) PI3K (1) Ras (1) RIP kinase (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148191

CL-197	HIV Protease	Infection Cardiovascular Disease Inflammation/Immunology Cancer
CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI). CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases . CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133124

PARP/PI3K-IN-1	PARP PI3K Apoptosis	Cancer
PARP/PI3K-IN-1 (compound 15) is a potent PARP/PI3K inhibitor with pIC₅₀ values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases .

HY-152860

Darizmetinib HRX-0215	p38 MAPK JNK NF-κB MDM-2/p53	Cancer
Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts .

HY-160412

TNFα activity modulator 3	NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
TNFα activity modulator 3 (example 6) is a modulator of TNF activity that inhibits TNFα-induced NF-κB activation and can be utilized in relevant research .

HY-151094

FTEAA	Monoamine Oxidase	Neurological Disease
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC₅₀s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research .

HY-138746

EGFR-IN-15	EGFR	Cancer
EGFR-IN-15 (compound I-005) is a EGFR inhibitor with an IC₅₀ of 4 nM. EGFR-IN-15 can be used for oncological diseases research .

HY-132129

SOS1-IN-2	Ras	Cancer
SOS1-IN-2 (Compound 1-1) is an inhibitor of SOS1 with an IC₅₀ value of 5 nM. SOS1-IN-2 can be used in tumor research .

HY-162424

ZBP1/RIP3/MLKL activator 1	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthetically derived quinoline compound. ZBP1/RIP3/MLKL Activator 1 induces DNA damage, enhances intracellular levels of reactive oxygen species (ROS), and triggers apoptosis via the caspase pathway. Furthermore, when apoptosis is inhibited, ZBP1/RIP3/MLKL Activator 1 promotes necroptotic cell death through the ZBP1-RIP3-MLKL pathway. ZBP1/RIP3/MLKL Activator 1 is utilized in oncological research, particularly in the selective targeting of cells with impaired apoptotic function .

Cat. No.	Product Name

HY-L100

Tumorigenesis-Related Compound Library	136 compounds
Cancer is a multi-step process which involves initiation, promotion and progression. Chemical carcinogens can alter any of these processes to induce their carcinogenic effects. People are continuously exposed exogenously to varying amounts of chemicals that have been shown to have carcinogenic or mutagenic properties in experimental systems. Exposure can occur exogenously when these agents are present in food, air or water, and also endogenously when they are products of metabolism or pathophysiologic states such as inflammation. The administration of chemical carcinogens is one of the most commonly used methods to induce tumors in several organs in laboratory animals in order to study oncologic diseases of humans. MCE offers a unique collection of 136 chemical carcinogens which have been identified with carcinogenic activity either in humans or in animal models. MCE Tumorigenesis-Related Compound Library is a powerful tool for studying oncologic diseases of humans. Standard opration based on safety data sheet will not cause harm to the body.

Tumorigenesis-Related Compound Library

136 compounds

Cancer is a multi-step process which involves initiation, promotion and progression. Chemical carcinogens can alter any of these processes to induce their carcinogenic effects. People are continuously exposed exogenously to varying amounts of chemicals that have been shown to have carcinogenic or mutagenic properties in experimental systems. Exposure can occur exogenously when these agents are present in food, air or water, and also endogenously when they are products of metabolism or pathophysiologic states such as inflammation. The administration of chemical carcinogens is one of the most commonly used methods to induce tumors in several organs in laboratory animals in order to study oncologic diseases of humans. MCE offers a unique collection of 136 chemical carcinogens which have been identified with carcinogenic activity either in humans or in animal models. MCE Tumorigenesis-Related Compound Library is a powerful tool for studying oncologic diseases of humans. Standard opration based on safety data sheet will not cause harm to the body.

Cat. No.	Product Name		Classification

HY-148191

CL-197		Alkynes
CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI). CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases . CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.